Ranbaxy surprises with Q4 loss, sees modest sales growth in 2013

MUMBAI Tue Feb 26, 2013 4:21pm IST

A patient holds free medicine provided by the government at Rajiv Gandhi Government General Hospital (RGGGH) in Chennai July 12, 2012. REUTERS/Babu/Files

A patient holds free medicine provided by the government at Rajiv Gandhi Government General Hospital (RGGGH) in Chennai July 12, 2012.

Credit: Reuters/Babu/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Ranbaxy Laboratories Ltd(RANB.NS), India's top drugmaker by sales, said its base business would grow a modest 10 percent in 2013 after reporting a surprise quarterly loss on product recall charges, sending its shares down more than 4 percent.

Controlled by Japan's Daiichi Sankyo Co (4568.T), Ranbaxy reported a quarterly net loss of 4.92 billion rupees after setting aside 1.86 billion rupees towards recall costs. Analysts on average had estimated consolidated net profit at 1.44 billion rupees on net sales of 26.96 billion rupees, according to Thomson Reuters I/B/E/S.

The drugmaker in November voluntarily recalled its cholesterol lowering generic of Lipitor from the U.S. market after it discovered contamination with tiny glass particles in certain lots of 10mg, 20mg and 40mg doses of the drug.

"This is really bad. This raises serious questions about transparency," said Daljeet Kohli, head of research at brokerage IndiaNivesh. "The company has been saying that this recall was voluntary and now it has made a huge provision for costs, which is not a good thing for any company to do."

After the product recall, Ranbaxy's market share of generic Lipitor fell to less than 3 percent, according to industry estimates. The drugmaker has now resumed supplying the United States.

Ranbaxy launched the first generic version of Pfizer's (PFE.N) Lipitor in 2011 and during its first six months on the market the company generated sales of nearly $600 million, according to analysts estimates.

The company said it expects to achieve sales of over 120 billion rupees in the current fiscal year ending December, compared to 124.6 billion rupees reported in 2012.

Q4 NUMBERS DISAPPOINT

Ranbaxy said consolidated sales fell 28.8 percent to 26.71 billion rupees in the fiscal fourth quarter ended December. Sales in its key North America market fell to 8.51 billion rupees in October-December compared to $407 million in the year earlier when the company gained from exclusive rights to sell generic Lipitor in the United States.

Global demand for cheaper generic medicines from companies like Ranbaxy and local rivals Dr. Reddy's Laboratories Ltd (REDY.NS), Cipla Ltd (CIPL.NS) and Sun Pharmaceutical Industries Ltd (SUN.NS) is booming as developed nations battle rising healthcare costs.

The drugmakers however, face intense competition as well as an increase in lawsuits from rival drugmakers and a stricter U.S. regulatory environment.

Valued at $3.2 billion, shares in Ranbaxy fell 3.95 percent at 416.70 rupees on Tuesday when the Mumbai market was down 1.64 percent. The shares have fallen 17.6 percent this year compared to a 3.2 percent drop in the BSE healthcare index.

(Reporting by Kaustubh Kulkarni; Editing by Matt Driskill)

FILED UNDER:

REUTERS EXCLUSIVE

Reuters Showcase

Documents' Leak

Documents' Leak

India widens oil leaks probe to defence ministry  Full Article 

Jim O’Neill Interview

Jim O’Neill Interview

'India can become world’s fifth-largest economy by decade’s end'  Full Article 

Food Security

Food Security

India will not cut multi-billion dollar food handout programme - PM  Full Article 

Bharti-China Mobile

Bharti-China Mobile

Bharti Airtel, China Mobile to collaborate on 4G  Full Article 

Suzlon Energy

Suzlon Energy

Suzlon expects to turn profitable in fiscal 2016: chairman   Full Article 

Eicher Motors Stake

Eicher Motors Stake

Volvo selling up to $300 mln worth of Eicher shares  Full Article 

Rich List

Rich List

Bill Gates tops Forbes rich list, Michael Jordan joins.  Full Article 

Tough Task

Tough Task

India needs sustained GDP growth of 9-10 percent - Jaitley.  Full Article 

Budget 2015

Budget 2015

Budget announcements and reactions from the industry  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage